Aequus Pharmaceuticals (TSXV:AQS; OTCQB:AQSZF) announced a collaboration agreement with Scientus Pharma to develop a cannabinoid containing transdermal formulation to treat resistant epilepsy.
As quoted in the press release:

They have signed a non-binding term sheet on a collaboration to develop, assess clinical performance, and commercialize a cannabinoid containing transdermal formulation designed and optimized to address both acute and chronic treatment of Resistant Epilepsy, and certain other neurological disorders.
Scientus will be the supplier of specific cannabinoid extracts and will have an option to co-fund the clinical development of this program. The parties expect to expand the collaboration to additional product development programs in the future.
“We are delighted to collaborate with Scientus for development and commercial supply as we advance this first product, a pharmaceutical-grade, transdermal cannabinoid based therapy for use in epilepsy and potentially other additional neurological disorders,” said Doug Janzen, Chairman and CEO of Aequus. “Within only three months of announcing our involvement in the medical cannabis space, we’ve completed a comprehensive survey with physicians identifying current challenges and validating our product concepts, partnered with the Centre for Drug Research and Development (CDRD) for formulation development, and have now formed a product specific relationship with a high quality, medically focused Licensed Dealer who shares our vision to improve the quality of cannabis-based options currently available in progressive markets, such as Canada.”


Click here to read the full press release.

Source: www.marketwired.com

The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.

Also this week, new data showed sales of Canadian cannabis edible products may be stalling.

Keep reading... Show less

The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.

Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.

Keep reading... Show less

The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.

Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .

Keep reading... Show less
  • On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
  • On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
  • To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
  • The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
  • Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
  • Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
  • Company to release Q3 2020 financials and host webcast on Tuesday, December 1st

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products.  Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.

Keep reading... Show less

Recap of special management call includes upcoming corporate milestones and details of proposed combination with established beverage manufacturer

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV, OTCQB:BVNNF, FSE:7BC) (“BevCanna” or the “Company”) is pleased to provide a recorded recap of the special management call held on Tuesday November 24, 2020. The call discussed upcoming corporate milestones and reviewed recent developments at the developer and manufacturer of cannabinoid‐infused beverages and consumer products for in‐house brands and white label clients.

Keep reading... Show less